These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

114 related articles for article (PubMed ID: 23977829)

  • 1. Cardiovascular disease in women: contraceptive issues and nonvalvular cardiovascular disease.
    Schrager S; Dalby J; Hayon R; Fox K
    FP Essent; 2013 Aug; 411():28-33. PubMed ID: 23977829
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Combined oral contraceptives in polycystic ovary syndrome - indications and cautions.
    Bozdag G; Yildiz BO
    Front Horm Res; 2013; 40():115-27. PubMed ID: 24002409
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Glucose intolerance, insulin resistance and cardiovascular risk factors in first degree relatives of women with polycystic ovary syndrome.
    Yilmaz M; Bukan N; Ersoy R; Karakoç A; Yetkin I; Ayvaz G; Cakir N; Arslan M
    Hum Reprod; 2005 Sep; 20(9):2414-20. PubMed ID: 15890734
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Hormones and cardiovascular health in women.
    ESHRE Capri Workshop Group
    Hum Reprod Update; 2006; 12(5):483-97. PubMed ID: 16807276
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cardiovascular effects of oral contraceptives: a review.
    Stubblefield PG
    Int J Fertil; 1989; 34 Suppl():40-9. PubMed ID: 2576258
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Contraceptive methods and risk factors of cardiovascular diseases in Tehranian women: Tehran Lipid and Glucose Study.
    Azizi F; Ainy E; Mirmiran P; Habibian S
    Eur J Contracept Reprod Health Care; 2002 Mar; 7(1):1-6. PubMed ID: 12041858
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Results of oral contraceptive epidemiologic studies regarding neoplastic and cardiovascular effects.
    Grimes DA
    Int J Fertil; 1989; 34 Suppl():27-33. PubMed ID: 2576254
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Metabolic alterations and cardiovascular risk factors in the polycystic ovary syndrome.
    Pasquali R; Patton L; Pagotto U; Gambineri A
    Minerva Ginecol; 2005 Feb; 57(1):79-85. PubMed ID: 15758867
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Long-term health consequences of polycystic ovaries syndrome: metabolic, cardiovascular and oncological aspects].
    Gutman G; Geva E; Lessing JB; Amster R
    Harefuah; 2007 Nov; 146(11):889-93, 908. PubMed ID: 18087838
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Metabolic and cardiovascular consequences of polycystic ovary syndrome.
    Orio F; Vuolo L; Palomba S; Lombardi G; Colao A
    Minerva Ginecol; 2008 Feb; 60(1):39-51. PubMed ID: 18277351
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cardiovascular diseases attributable to hysterectomy: a population-based study.
    Kharazmi E; Fallah M; Luoto R
    Acta Obstet Gynecol Scand; 2007; 86(12):1476-83. PubMed ID: 17917816
    [TBL] [Abstract][Full Text] [Related]  

  • 12. European Society of Contraception oral contraceptives survey update: birth control methods in "Europe of the 12".
    Serfaty D; Wildemeersch D; Verougstraete A; Creatsas G
    Int J Fertil Menopausal Stud; 1995; 40 Suppl 2():73-9. PubMed ID: 8574253
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cardiovascular risk in women: focus on hypertension.
    Abramson BL; Melvin RG
    Can J Cardiol; 2014 May; 30(5):553-9. PubMed ID: 24786446
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Polycystic ovary syndrome and chronic inflammation: pharmacotherapeutic implications.
    Sirmans SM; Weidman-Evans E; Everton V; Thompson D
    Ann Pharmacother; 2012 Mar; 46(3):403-18. PubMed ID: 22388330
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The adverse effects of hormonal therapy.
    Bush TL
    Cardiol Clin; 1986 Feb; 4(1):145-52. PubMed ID: 3518931
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Polycystic ovary syndrome: a major unrecognized cardiovascular risk factor in women.
    Alexander CJ; Tangchitnob EP; Lepor NE
    Rev Cardiovasc Med; 2009; 10(2):83-90. PubMed ID: 19593320
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparison of metabolic and inflammatory outcomes in women who used oral contraceptives and the levonorgestrel-releasing intrauterine device in a general population.
    Morin-Papunen L; Martikainen H; McCarthy MI; Franks S; Sovio U; Hartikainen AL; Ruokonen A; Leinonen M; Laitinen J; Järvelin MR; Pouta A
    Am J Obstet Gynecol; 2008 Nov; 199(5):529.e1-529.e10. PubMed ID: 18533124
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Metabolic and cardiovascular impact of oral contraceptives in polycystic ovary syndrome.
    Soares GM; Vieira CS; de Paula Martins W; Dos Reis RM; de Sá MF; Ferriani RA
    Int J Clin Pract; 2009 Jan; 63(1):160-9. PubMed ID: 18795969
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Hormonal contraception--side effects and surgical aspects (author's transl)].
    Göretzlehner G; Carol W; Köhler G
    Zentralbl Chir; 1980; 105(24):1601-16. PubMed ID: 7015744
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Women, hormones and blood pressure.
    Khaw KT
    Can J Cardiol; 1996 Jun; 12 Suppl D():9D-12D. PubMed ID: 8665427
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.